RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic per procedure, and the enhanced treatment of fine wrinkles of the face, décolleté and hands
Today’s edition of the Financial Post (Oct 27, 2015) highlights three Canadian companies (RepliCel Life Sciences Inc., Hemostemix Inc. and Sernova Corp.) making a global impact on the regenerative medicine industry and the pivotal role the Centre for Commercialization of Regenerative Medicine (CCRM) is taking to leverage commercialization.
Researchers at The Francis Crick Institute in London want to use a controversial genetic technique to carry out research into infertility. The embryos would be destroyed after the research and not implanted into the womb. The government's fertility watchdog said it had received the application, which would be looked at in due course.